Not medical advice. DrPep does not sell peptides. Educational content only — many compounds are investigational or not FDA-approved. Verify against primary sources and talk with a licensed clinician.

Body map · Stacks

Tap a region on the figure (or a chip) to browse stacks people discuss for that area — same educational cards as the Stack tab. Not dosing. Catalog framing: 10 mg only. DrPep does not sell peptides.

Questions about a stack?

info@drpep.ai All stacks →

Male educational view — study-interest regions and notes framed for research reported in men. Not a personal recommendation or dose.

Educational anatomical figure with eight study-interest regions

Tap a body areaTap a body area — Brain, skin, digestive, immune, hormones, bones & muscle, heart / vascular, or sexual / reproductive — to open the scrolling peptide list for that area.

Open full body map

Educational only. Highlighted regions show where peptides are discussed in published research — not a diagnosis or treatment map. DrPep does not sell peptides.

#1Trending10/10 mg

CJC-1295 / Ipamorelin

CJC-1295 (no DAC) · Ipamorelin

People pair a GHRH-pathway analog (CJC-1295 without DAC) with a selective growth-hormone secretagogue (ipamorelin) because each hits a different receptor lane on the GH axis. Community and clinic menus treat them as complementary “related compounds,” not because a labeled combo product exists.

GH-axis / IGF-I research literacy
Body-composition discussion themes
Comparing short-acting GHRH analogs vs DAC versions
Understanding GHRH vs GHS receptor pathways

Evidence

No published randomized trial administers CJC-1295 together with ipamorelin in humans. Component evidence: Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) showed CJC-1295 (DAC form in that program) raised GH/IGF-I in healthy adults; Raun et al., Eur J Endocrinol 1998 (PMID 9849822) characterized ipamorelin as a selective GHS. Older GHRH+GHRP co-admin work suggests pathway interaction, but that is not the same as proving this wellness stack. Honest gap: combo efficacy/safety in humans is untested.

Regions: hormones, bones · Stack tab

#2Trending10/10 mg

CJC-1295 (DAC) / Ipamorelin

CJC-1295 with DAC · Ipamorelin

DAC (Drug Affinity Complex) versions are discussed when people want a longer-residence GHRH analog next to a pulse-style GHS. Catalogs often list the pair so readers can compare half-life stories — not as FDA-endorsed co-therapy.

Longer-acting GHRH analog literacy
GH-axis research interest
Catalog naming: DAC vs no-DAC
Why “trending synergy” claims outpace trials

Evidence

Human PK/PD for CJC-1295 with albumin-binding extension comes from Teichman et al. 2006 (JCEM; PMID 16352683). Ipamorelin evidence remains separate (Raun 1998). There is still no indexed interventional trial of DAC-CJC-1295 + ipamorelin as a fixed stack. Orthopedic peptide primers (e.g. narrative reviews in sports-medicine literature, 2025–2026) explicitly note the combination’s clinical evidence base as absent.

Regions: hormones, bones · Stack tab

#3Trending10/10 mg

Sermorelin / Ipamorelin

Sermorelin · Ipamorelin

Sermorelin (GHRH 1–29 fragment analog) plus ipamorelin is a common clinic-menu and community “GH-axis pair,” framed as a shorter-acting GHRH tool beside a selective secretagogue. People compare it with CJC-based pairs when shopping catalogs.

GHRH-fragment vs GHS literacy
Clinic-menu comparison reading
Body-comp / recovery discussion themes
Recognizing historical vs current regulatory status

Evidence

Sermorelin has a historical clinical footprint as a GHRH analog (formerly used in diagnostic/therapeutic GH contexts; U.S. commercial status has shifted over time). Ipamorelin’s selectivity profile is described in Raun et al. 1998. No robust modern RCT establishes sermorelin+ipamorelin as a consumer stack for body composition or anti-aging. Treat co-vialing as packaging, not a labeled combination drug.

Regions: hormones, bones · Stack tab

#4Trending10/10 mg

Tesamorelin / Ipamorelin

Tesamorelin · Ipamorelin

Readers stack an FDA-approved GHRH analog story (tesamorelin / Egrifta® for a specific HIV-lipodystrophy indication) next to research GHS talk (ipamorelin). The educational hook is literacy — approved-drug labeling does not authorize informal research-peptide stacking.

Visceral-fat / GHRH label literacy (tesamorelin)
Separating approved indication from gray-market stacks
GH-axis research curiosity
Why “approved + research” ≠ combo approval

Evidence

Tesamorelin has strong indication-specific evidence: Falutz et al., NEJM 2007; pooled phase 3 analysis Falutz et al., JCEM 2010 (PMID-linked VAT reduction ~15% vs placebo in HIV abdominal lipohypertrophy). Ipamorelin is not an approved companion. No trial validates tesamorelin+ipamorelin as a general fat-loss or wellness stack outside labeled use.

Regions: hormones, digestive · Stack tab

#510/10 mg

Tesamorelin / Sermorelin

Tesamorelin · Sermorelin

This pair shows up when people compare two GHRH-pathway analogs rather than GHRH+GHS. Useful for naming literacy — dual GHRH analogs in one research vial do not create a labeled dual-GHRH therapy.

GHRH analog family literacy
Catalog comparison skills
Endocrine research interest
Avoiding dual-GHRH regimen assumptions

Evidence

Tesamorelin’s VAT evidence is indication-specific (phase 3 HIV lipodystrophy program). Sermorelin’s evidence base is older and separate. There is no high-quality trial of tesamorelin co-administered with sermorelin for wellness outcomes. Educational value is pathway comparison, not stacking advice.

Regions: hormones · Stack tab

#6Trending10/10 mg

BPC-157 / TB-500 (“Wolverine”)

BPC-157 · TB-500

The most-named “repair” duo in community language: BPC-157 (gastric-derived pentadecapeptide research) with TB-500 (thymosin β4–related fragment). People group them because soft-tissue, tendon, and recovery chats often name both — overlapping themes, not a proven consumer protocol.

Soft-tissue / recovery research interest
Injury-model literature literacy
Separating animal signal from human proof
Understanding “Wolverine” as community nickname, not a drug name

Evidence

Combination trials of BPC-157 + TB-500 in humans are essentially absent. BPC-157: 2026 systematic review (Acta Orthop Belg) found only three small, poor-quality human studies (n=30) and graded certainty very low; CEI scoping work found no adequate RCTs. TB-4/TB-500: 2026 MDPI scoping review mapped mostly preclinical literature; direct TB-500 human evidence is minimal. Sports-medicine peptide primers urge caution. FDA has flagged related bulk substances in compounding risk materials.

Regions: bones, skin, digestive, heart · Stack tab

#7Trending10 mg catalog framing

GLOW (BPC-157 / GHK-Cu / TB-500)

BPC-157 · GHK-Cu · TB-500

GLOW bundles a repair duo with copper tripeptide-1 (GHK-Cu). People discuss it when soft-tissue and skin/appearance research chats overlap. Thematic stacking in conversation — not a cosmetic or medical claim.

Skin / tissue-appearance discussion themes
Soft-tissue research interest
Copper-peptide literacy beside repair peptides
Multi-peptide catalog decoding

Evidence

No controlled trial validates the three-way GLOW blend as a consumer product. GHK-Cu has a longer cosmetic/dermal research footprint than BPC or TB-500; BPC/TB evidence remains largely preclinical (see Wolverine notes). A branded triple does not create new approved indications.

Regions: skin, bones · Stack tab

#810 mg catalog framing

GLOW Plus (BPC-157 / GHK-Cu / TB-500 / Thymosin α1)

BPC-157 · GHK-Cu · TB-500 · Thymosin Alpha-1

Extends GLOW with thymosin alpha-1 for readers who want repair/skin themes plus immune-modulatory research chatter. More components do not mean more proven benefit.

Skin / tissue discussion
Immune-research curiosity
Multi-peptide literacy
Recognizing branded “Plus” SKUs as packaging

Evidence

Thymosin α1 has a separate clinical/research history (immune-oncology and infection literature in various jurisdictions) from BPC/TB/GHK. Published evidence for this specific four-peptide consumer stack is not established. Read each component’s literature on its own.

Regions: skin, immune, bones · Stack tab

#9Trending10 mg catalog framing

KLOW (BPC-157 / GHK-Cu / TB-500 / KPV)

BPC-157 · GHK-Cu · TB-500 · KPV

KLOW keeps the GLOW repair/skin theme and adds KPV (a short melanocortin-related tripeptide) often mentioned in gut/inflammation research chats.

Gut / inflammation discussion themes
Skin / tissue discussion
Decoding four-component SKUs
Separating preclinical KPV signal from stack claims

Evidence

KPV appears in inflammatory and barrier-model research as a tripeptide fragment; evidence quality varies and human outcome trials for wellness stacks are lacking. No RCT establishes KLOW as a validated regimen. Multi-peptide brand blends should be read as catalog products.

Regions: skin, digestive, immune · Stack tab

#10Trending10/10 mg

Selank / Semax

Selank · Semax

Two synthetic neuropeptide analogs frequently listed together in cognitive/stress research conversations: Selank (tuftsin-related) and Semax (ACTH-fragment–related). Community interest tags focus and mood — not proof the blend improves cognition.

Cognitive research interest
Stress / mood discussion themes
Neuropeptide naming literacy
Cross-border regulatory status awareness

Evidence

Selank and Semax have research histories largely outside U.S. FDA wellness-approval pathways; evidence quality and regulatory status vary by country. Combination RCTs for a fixed Selank/Semax consumer stack in U.S. populations are not a strong, established evidence base. Educational framing only.

Regions: brain · Stack tab

#1110/10 mg

CUPRA (GHK-Cu / AHK-Cu)

GHK-Cu · AHK-Cu

Copper-coordinated tripeptides paired for skin/tissue research interest. People compare GHK-Cu and AHK-Cu when reading dermal and hair/skin roundups.

Skin / tissue discussion
Copper-peptide literacy
Cosmetic-research curiosity
Catalog decoding for Cu-peptide SKUs

Evidence

GHK-Cu is among the better-documented cosmetic research peptides (wound/dermal literature over decades). AHK-Cu appears in similar dermal-research conversations with thinner clinical depth. The dual copper blend is not an approved drug product; orthopedic peptide reviews note insufficient musculoskeletal clinical data for GHK-Cu.

Regions: skin · Stack tab

#1210 mg catalog framing

INVICTUS (TB-500 / KPV / Thymosin α1)

TB-500 · KPV · Thymosin Alpha-1

Named trio mixing thymosin-family repair/immune talk with KPV’s inflammation chatter. Educational value is recognizing components when a brand SKU appears.

Immune-research curiosity
Inflammation discussion
Recovery talk themes
Brand-SKU component literacy

Evidence

Each peptide has its own literature lane; the branded trio is not a validated clinical regimen. TB-500 human musculoskeletal evidence is sparse (2026 scoping review); KPV and thymosin α1 should be weighed separately.

Regions: immune, bones, digestive · Stack tab

#13Trending10/10 mg

REGEN (BPC-157 / KPV)

BPC-157 · KPV

Pairs “repair” talk (BPC-157) with short anti-inflammatory peptide talk (KPV). Popular in gut and soft-tissue community threads.

Gut discussion themes
Inflammation discussion
Soft-tissue research interest
Reading dual-peptide SKUs critically

Evidence

No high-quality human RCT establishes BPC-157+KPV as a gut or repair protocol. BPC-157 human evidence remains very low certainty; KPV evidence is largely preclinical/mechanistic. Dual vials are packaging.

Regions: digestive, immune, bones · Stack tab

#1410/10 mg

VESPER (PT-141 / Oxytocin)

PT-141 · Oxytocin

Appears in intimacy and social-bonding research conversations. PT-141 is discussed alongside the approved melanocortin agonist bremelanotide (Vyleesi®) story; oxytocin brings bonding/social research themes.

Sexual-health literacy (approved vs research)
Melanocortin pathway discussion
Social / bonding research interest
Why labeled drugs ≠ blend permission

Evidence

Bremelanotide is FDA-approved for a specific sexual-desire indication in premenopausal women — that label does not cover gray-market PT-141 blends or oxytocin co-stacks. Oxytocin has extensive separate research. No solid trial validates VESPER-style blends as consumer intimacy products.

Regions: sexual, brain · Stack tab

#1510 mg catalog framing

VOCUS (Selank / Semax / Pinealon)

Selank · Semax · Pinealon

Three-neuropeptide catalogs aimed at cognitive / sleep / aging research chat. Useful for decoding a complex SKU into known library names.

Cognitive research interest
Neuropeptide literacy
Aging-research curiosity
SKU decoding skills

Evidence

Heterogeneous evidence and regulatory status across Selank, Semax, and pinealon. Multi-peptide branding is not clinical validation. Prefer component-level primary sources.

Regions: brain · Stack tab

#1610 mg catalog framing

VORTEX (GHK-Cu / Epithalon / SNAP-8 / KPV)

GHK-Cu · Epithalon · SNAP-8 · KPV

Appearance-oriented discussions mix copper peptides, epithalon (telomere/aging research chatter), SNAP-8 (cosmetic signal peptide), and KPV. Decode the SKU; don’t assume anti-aging drug status.

Skin / appearance discussion
Cosmetic-research curiosity
Multi-peptide literacy
Separating cosmetic peptides from drug claims

Evidence

SNAP-8 and GHK-Cu sit closer to cosmetic research; epithalon and KPV have separate investigational lanes. No blend creates FDA-approved anti-aging drug status. Evidence for the four-way combo is catalog-level, not trial-level.

Regions: skin · Stack tab

#1710/10 mg

BPC-157 / GHK-Cu

BPC-157 · GHK-Cu

A lighter “repair + copper” pair without TB-500 — discussed when people want soft-tissue themes next to dermal copper-peptide interest but prefer a two-component story.

Soft-tissue + skin overlap themes
Two-component catalog literacy
Copper-peptide vs repair-peptide roles
Evidence-gap awareness

Evidence

Component literatures do not combine into a validated duo trial. BPC-157: very low human certainty; GHK-Cu: stronger cosmetic/dermal research footprint but limited musculoskeletal clinical data per sports-medicine reviews.

Regions: skin, bones · Stack tab

#1810/10 mg

Ipamorelin / GHRP-2

Ipamorelin · GHRP-2

Classic dual-GHS discussion: two ghrelin-receptor pathway tools compared for selectivity (ipamorelin) vs potency/cortisol tradeoffs (GHRP-2). Older community stacks; still appears in catalogs and forums.

GHS selectivity literacy
Historical dual-secretagogue stacks
GH-axis research interest
Why “more GHS” ≠ better evidence

Evidence

Ipamorelin’s selective profile is described in Raun et al. 1998 (less ACTH/cortisol vs some GHRPs in animal models). GHRP-2 has separate secretagogue literature. Human RCTs of ipamorelin+GHRP-2 as a fixed wellness stack are not a strong modern evidence base.

Regions: hormones, bones · Stack tab

#1910/10 mg

Ipamorelin / GHRP-6

Ipamorelin · GHRP-6

Another dual-GHS pairing from classic peptide forums. People compare appetite/cortisol chatter around GHRP-6 with ipamorelin’s “cleaner GH” reputation in community language.

Dual-GHS catalog literacy
Appetite / cortisol discussion themes (community)
GH-axis research interest
Historical vs current stack fashion

Evidence

Both are GHS-R agonists studied separately; GHRP-6 has a long preclinical and some human secretagogue history. No robust modern combination trial endorses ipamorelin+GHRP-6 for body-composition claims. Educational comparison only.

Regions: hormones, bones · Stack tab

#20Trending10/10 mg

MOTS-c / Humanin

MOTS-c · Humanin

Mitochondrial-derived peptide (MDP) pair discussed in metabolic aging and cellular-stress research chats. Rising popularity signal as “mito peptide” literacy spreads beyond GH-axis stacks.

Mitochondrial / metabolic research interest
Aging-biology literacy
Separating MDP hype from trial maturity
New-wave stack awareness beyond GH/repair

Evidence

MOTS-c and humanin have expanding preclinical and early translational literature on metabolic and stress-response pathways; human clinical outcome programs remain limited relative to their online popularity. No established consumer-stack RCT for the pair. Educational framing of research interest only.

Regions: digestive, heart, hormones · Stack tab